

VINCENZO PAVONE MD
EDUCATION AND WORK CURRICULUM

Department of Haematology, Haemopoietic stem cell transplantation and Transfusion
Unit in "Card. G. PANICO" Hospital
S.Pio X, 4
73039 Tricase (Lecce)-Italy

EDUCATION AND WORK EXPERIENCE:

Degree in Medicine, at Bari University, 8th November 1974; I was given the full mark.
1974 (January 1975): passed the qualifying exam for medical profession, 2° examination session.

Put on the Medical Register of Bari province, 19th February 1975.

Specialization in Clinical and Lab Hematology obtained at Bari University with honours, 14th July 1977.

House Physician, without wages, at Medical Clinic II Institute of Bari University, as from November 1974.

Full time **Medical Assistant** at Immuno-hematology and Hematology department of Putignano (BA) Hospital, from 6th October '75 to 28th February '78.

Hematology Medical Assistant at Consortium General Hospital in Bari (USL BA 4) in Hematology and Leukaemia United Department at Medical Clinic II Institute, as from 1st March 1978; **Assistant Lecturer** for Chair – Hematology Independent Service, from July '86 to 31st January '94.

Permanent Hematology Assistant as from 1st February '94. Official recognition of professional qualification according to the former Art. 117 DPR 384/90 Italian regulation, from 1st December '90 to 28th February '94; full time as from 1st July '91. **First salary level Medical Manager** for Hematology, with open-ended contract, from 1st January '98 to February 2005.

From 16th February 2005 **chief** of the Department of Haematology, Transfusion Medicine and Haemopoietic stem cell transplantation in "C. PANICO" Hospital, Tricase (Lecce). The Department is A complex operative unit of cCSE transplantation and infusion of CSE, immuno-effected cells / cell therapy products and it is an intensive care unit.

FUNCTIONAL POSITION

I was given the following **executive appointments**:

- 1998: **in charge of malignant lymphomas diagnostics and treatment** proper resolution n. 176 del 25/2/99, n. 472 of 19/4/99, n.2363 of 21/12/98;
- from 1st January '99 to 30th June '99, from 1st July '99 to 14th March '00 and from 15th March '00 to 31st October '00 (idem) proper resolution n.1730 of 30/12/99 and n.644 of 16/5/00, corresponding to the **Structure Manager appointment**.
- As from 1st November 2000, for three years: referent for malignant lymphomas diagnostics and treatment, resolution n.1354 of 31/10/00.
- **In charge of Simple Active Service Unit** for diagnosing the tardy complications after strong doses chemotherapy for malignant lymphomas treatment.

The qualitative and quantitative professional activity has been evaluated by the II Level Manager, in charge of Hematology Active Service Unit, of Medical Management and of Unit Management within the '90-'94 and '98-2001 periods.

STUDYING AND TEACHING ACTIVITIES

- **Head physician qualification**, according to the D.M. – health – 6th March 1986 (GU N°76 DEL 2/4/86) Italian regulation, 1983.
- **On BA9 Local Health Unit** order (Resolution n°1850 del 28/5/86), **Resident Doctor** at "**Léon Bérard**" **Ministère de la Santé onco-hematology Centre – Lyon** (France), managed by Doctor Thierry Philip in the Sterilized Unit and in the Cryobiological Labs in the field of Oncology Chemotherapy and of Marrow Transplantation, which I largely and responsibly performed (from the sample to the transplantation itself), from 1st December 1987 to 30th September 1988.
- **Lecturer at School for Trained Nurses**, Marina Militare of Taranto.
- **Hematology Lecturer** at "Sacro Cuore" in Bari General Hospital, for **three-year training course for trained nurses** (according to the resolution of 24/9/1987).
- **Teacher** in many **Refresher and Specialization Courses** organized held by the Medical Register (1987 and following years) as well as by Biologists of Bari, Matera and Brindisi provinces. Teacher in many other courses held in Italy and abroad at different levels, in different places and in different scientific communities, as certified in enclosures.

- **Teacher** of Integrative Didactics at **Specialization Schools** in Gerontology and Geriatrics, in Allergology and Clinical Immunology, managed by Clinical Medicine Institute of Bari University, as it was certified on 29th March 1993 by the Doctor Alfredo Tursi, Manager of the Clinical Medicine Institute.
- **Teacher** of Integrative Didactics at **Hematology Specialization School** of Bari University (Internal Medicine and Public Medicine Department). I was appointed to the teaching of “Instructions for using peripheral staminal cells in Non-Hodgkin Lymphomas Treatment” (as from 2000/2001 academic year).
- **Teacher** of Integrative Didactics at **Oncology Specialization School (DIMO)**.
- **Teacher** at Specialization Course in **Cells Characterization** in Oncology Hematology of Bari University Hematology Chair and Independent Service.
- **Teacher** of “Lympho-adenopathy Semiotics” on Appointment of Bari University.
- **Teacher** at parallel refresher courses of National Medicine Academy.
- **Professor** of Haematology 3 Years degree in Nursing science at University of Bari – Polo didattico formativo Az. Osp C. G. Panico Tricase

SCIENTIFIC AND RESEARCH ACTIVITY

As member of Steering Committee of Italian Lymphomas Inter-group, of Multi-regional Group for Malignant Lymphomas and of Apulia Group for Malignant Lymphomas Diagnosis and Treatment and as Member of Italian Haematology Society, Italian Medical Oncology Association, Southern Italy Oncology Group, Lab Medicine Italian Society, European Group for Blood and Marrow Transplantation (**EBMT**) as well as of Gruppo Italiano dei Trapianti di Midollo Osseo (**GITMO** – Italian Group for Marrow Transplantation), joined several perspective and multi-centric National and International Research Programmes, Regional Apulia Delegate of GITMO, Coordinator of Lymphoma working party of REP (Rete Ematologia Pugliese) ,Coordinator of Transplant Group of REP. **Investigator Meetings and Clinical Trials** concerning diagnostics and treatment of malignant lymphomas and transplantation with haematopoietic staminal cells. **Study Coordinator** of clinical trial “Safety and efficacy of Zevalin combined with high-dose BEAM and autologous stem cell transplantation for the treatment of relapsed-refractory non Hodgkin lymphomas: results of an Italian multicenter study” (63 patients enrolled in 13 italian centres) and “A phase II study of chemotherapy, mobil and g-csf as mobilizing therapy for double autologous transplantation (asct) in patients with relapsed

or refractory diffuse large b cell non hodkin lymphoma (dlbc), pet positive after two r-dhap" (a multicenter Italian study). **Principal Investigator** of more than 15 other clinical trial.

I have received a GCP training during the previous clinical trials conducted during year 2010.

Since 1981, I joined all the Haematology Society meetings as well as several National and International Congresses, presenting reports and communications in more than thirty meetings.

SCIENTIFIC PUBLICATIONS

- 210 publications printed and published in national and international reviews (Bone Marrow Transplantation Journal, Leukemia & Lymphoma, Hematologica, Annals of Hematology, Blood, Annals of Oncology, Tumori, Chirurgia, Radiologia Medica, Bloot, Int. J. Immunotherapy, etc.), mainly about usage of strong doses chemotherapy and Staminal Cells Transplantation in Onco-hematology.
- Co-author of the book titled "Blood Diseases and Nursing Assistance" published by McGraw-Hill.

In 1991 I started up the transplant surgery both at medulla staminal cells and then peripheral blood cells sample level, at handling, decontamination and cryo-congelation of these cells level, and at clinical management of patients hospitalized in the **Sterilized Active Service Unit of Hematology** managed by Prof Liso.

Since then, we carried out more then 200 transplants with haemopoietic stem cells for the treatment of onco-hematological pathologies, as can be inferred by report of European Group for Blood and Marrow Transplantation (**EBMT**) and **National Transplantations Book**, of which I am the referent for my team.

I also started up the Marrow Donors Samples Centre for the **International Bone Marrow Donor Registry (IBMDR)**.

¹⁾ Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, Liso V, Perrone T, Liso A. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation.

Bone Marrow Transplant. 2006 Apr;37(8):719-24.

- 2) Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Clin Cancer Res. 2006 Jan 15;12(2):529-35.
- 3) Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.J Clin Oncol. 2005 Dec 20;23(36):9198-207.
- 4) Rigacci L, Federico M, Martelli M, Zinzani PL, Cavanna L, Bellesi G, Merli F, Alterini R, Petrucci MT, Tani M, Liberati AM, Vitolo U, Pavone V, Cuneo A, Chisesib T, Brugiatelli M; Intergruppo Italiano Linfomi. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma. 2003 Nov;44(11):1911-7.
- 5) Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, Vitolo U, Angelucci E, Boccadoro M, Gallo E, Mandelli F; Intergruppo Italiano Linfomi (IIL). VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study.Ann Oncol. 2004 Jan;15(1):123-8.
- 6) Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant. 2002 Feb;29(4):285-90.
- 7) Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L, Resegotti L. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood. 2000 Feb 1;95(3):783-9.

- 8) Guarini A, Pavone V, Valentino T, Rana A, Di Vagno G, Maiorano E, Liso V. Primary non Hodgkin's lymphoma of the vagina. *Leuk Lymphoma*. 1999 Nov;35(5-6):619-22. Review.
- 9) Vitolo U, Liberati AM, Cabras MG, Federico M, Angelucci E, Baldini L, Boccomini C, Brugiatelli M, Calvi R, Ciccone G, Genua A, Deliliers GL, Levis A, Parvis G, Pavone E, Salvi F, Sborgia M, Gallo E; Intergruppo Italiano Linfomi. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. *Haematologica*. 2005 Jun;90(6):793-801.
- 10) Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. *Cancer*. 2003 Jun 1;97(11):2748-59.
- 11) Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJ, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, Alinari L, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. *Haematologica*. 2002 Dec;87(12):1258-64.
- 12) Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannina D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, Alinari L, Baccarani M, Tura S. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. *Ann Oncol*. 2002 Sep;13(9):1364-9.
- 13) Zinzani PL, Martelli M, Bendandi M, De Renzo A, Zaccaria A, Pavone E, Bocchia M, Falini B, Gobbi M, Gherlinzoni F, Stefoni V, Tani M, Tura S. Primary mediastinal

large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. *Haematologica*. 2001 Feb;86(2):187-91.

- 14) Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term? *Haematologica*. 1999 Nov;84(11):996-1001.
- 15) Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, Gentilini P, Guardigni L, Gobbi M, Fattori PP, Falini B, Lauta VM, Bendandi M, Gherlinzoni F, De Renzo A, Zaja F, Mazza P, Volpe E, Bocchia M, Aitini E, Tabanelli M, Leone G, Tura S. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. *Blood*. 1999 Jul 1;94(1):33-8.
- 16) Zinzani PL, Martelli M, Magagnoli M, Zaccaria A, Ronconi F, Cantonetti M, Bocchia M, Marra R, Gobbi M, Falini B, Gherlinzoni F, Moretti L, De Renzo A, Mazza P, Pavone E, Sabattini E, Amendola A, Bendandi M, Pileri SA, Mandelli F, Tura S. Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. *Blood*. 1998 Aug 1;92(3):790-4.
- 17) Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. *Blood*. 1997 Jun 1;89(11):3974-9.
- 18) Favrot M, Philip I, Combaret V, Pavone E, Bouffet E, Biron P, Philip T. Monoclonal antibodies and complement purged autograft in Burkitt lymphoma and lymphoblastic leukemia. *Bone Marrow Transplant*. 1989 Jan;4 Suppl 1:202-4.
- 19) Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study, Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, J Clin Oncol. 2016 Apr 20;34(12):1376-85. doi: 10.1200/JCO.2015.63.0699.
- 20) Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients, Zinzani PL, Pellegrini C, Cantonetti M, Re A, Pinto A, Pavone V, Rigacci L, Celli M, Broccoli A, Argnani L, Pulsoni A., Oncologist. 2015 Dec;20(12):1413-6. doi: 10.1634/theoncologist.2015-0227.
- 21) Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP). Delia M, Carluccio P, Buquicchio C, Vergine C, Greco G, Amurri B, Melpignano

- A, Melillo L, Cascavilla N, Guarini A, Capalbo S, Tarantini G, Mazza P, Pavone V, Di Renzo N, Specchia G., Leuk Res. 2015 Aug 20. pii: S0145-2126(15)30358-1. doi: 10.1016/j.leukres.2015.08.005.
- 22) Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)., Caira M, Candoni A, Verga L, Busca A, Delia M, Nosari A, Caramatti C, Castagnola C, Cattaneo C, Fanci R, Chierichini A, Melillo L, Mitra ME, Picardi M, Potenza L, Salutari P, Vianelli N, Facchini L, Cesarini M, De Paolis MR, Di Blasi R, Farina F, Venditti A, Ferrari A, Garzia M, Gasbarrino C, Invernizzi R, Lessi F, Manna A, Martino B, Nadali G, Offidani M, Paris L, Pavone V, Rossi G, Spadea A, Specchia G, Trecarichi EM, Vacca A, Cesaro S, Perriello V, Aversa F, Tumbarello M, Pagano L; Haematologica. 2015 Feb;100(2):284-92. doi: 10.3324/haematol.2014.113399.
 - 23) Azacitidine in the front-line treatment of therapy-related myeloid neoplasms: a multicenter case series. Minoia C, Sgherza N, Loseto G, Greco G, Buquicchio C, Merchionne F, Toldo C, Galise I, Melpignano A, Tarantini G, Pavone V, Guarini A. Anticancer Res. 2015 Jan;35(1):461-6.
 - 24) Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis., Merchionne F, Quintana G, Gaudio F, Minoia C, Specchia G, Guarini A, Quarta G, Pavone V, Melpignano A., Leuk Res. 2014 Dec;38(12):1446-50. doi: 10.1016/j.leukres.2014.10.001.
 - 25) Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial., Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G; Fondazione Italiana Linfomi, Lancet Oncol. 2014 Jun;15(7):730-7. doi: 10.1016/S1470-2045(14)70191-3.
 - 26) Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma, Lanza F, Lemoli RM, Olivieri A, Laszlo D, Martino M, Specchia G, Pavone V, Imola M, Pasini A, Milone G, Scortechini I, Todisco E, Guggiari E, Cascavilla N, Martinelli G, Rambaldi A, Bosi A., Transfusion. 2014 Feb;54(2):331-9. doi: 10.1111/trf.12265. Erratum in: Transfusion. 2014 Jun;54(6):1688-91.
 - 27) Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study., Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, Derenzini E, Broccoli A, Gandolfi L, Quirini F, Casadei B, Argnani L, Baccarani M, Hematol Oncol. 2013 Dec;31(4):179-82. doi: 10.1002/hon.2036.
 - 28) Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination., Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, Bellio L, Botto B, Bulian P, Cantonetti M, Depaoli L, Di Renzo N, Di Rocco A, Evangelista A, Franceschetti S, Godio L, Mannelli F, Pavone V, Pioltelli P, Vitolo U, Pogliani EM; Fondazione Italiana, Blood. 2012 Oct 18;120(16):3222-8. doi: 10.1182/blood-2012-04-423095.
 - 29) Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program, Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, Lunghi M, D'Arco AM, Levis A, Pastore D, Di Renzo N, Santagostino A, Pavone V, Buccisano F, Musto P., Cancer. 2012 Feb 15;118(4):1014-22. doi: 10.1002/cncr.26354
 - 30) Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas., Gaudio F, Giordano A, Pavone V, Perrone T, Curci P, Pastore D, Delia M, De' Risi C, Spina A, Liso V, Specchia G., Adv Hematol. 2011;2011:707542. doi: 10.1155/2011/707542.
 - 31) Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation, Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, Liso V, Perrone T, Liso A., Bone Marrow Transplant. 2006 Apr;37(8):719-24.
 - 32) MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors, Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F,

- Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M., Clin Cancer Res. 2006 Jan 15;12(2):529-35.
- 33) ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi, Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi, J Clin Oncol. 2005 Dec 20;23(36):9198-207.
- 34) The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 case, Rigacci L, Federico M, Martelli M, Zinzani PL, Cavanna L, Bellesi G, Merli F, Alterini R, Petrucci MT, Tani M, Liberati AM, Vitolo U, Pavone V, Cuneo A, Chisesib T, Brugiatelli M; Intergruppo Italiano Linfomi, Leuk Lymphoma. 2003 Nov;44(11):1911-7.
- 35) VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study., Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, Vitolo U, Angelucci E, Boccadoro M, Gallo E, Mandelli F; Intergruppo Italiano Linfomi (IIL), Ann Oncol. 2004 Jan;15(1):123-8.
- 36) Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma, Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V., Bone Marrow Transplant 2002 Feb;29(4):285-90.
- 37) Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi., Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L, Resegotti L., Blood. 2000 Feb 1;95(3):783-9.
- 38) Primary non Hodgkin's lymphoma of the vagina, Guarini A, Pavone V, Valentino T, Rana A, Di Vagno G, Maiorano E, Liso V., Leuk Lymphoma 1999 Nov;35(5-6):619-22. Review.
- 39) High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial, Vitolo U, Liberati AM, Cabras MG, Federico M, Angelucci E, Baldini L, Boccomini C, Brugiatelli M, Calvi R, Ciccone G, Genua A, Deliliers GL, Levis A, Parvis G, Pavone E, Salvi F, Sborgia M, Gallo E; Intergruppo Italiano Linfomi, Haematologica. 2005 Jun;90(6):793-801.
- 40) High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence., Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A, Cancer. 2003 Jun 1;97(11):2748-59.
- 41) Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients., Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJ, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, Alinari L, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, Cavalli F; International Extranodal Lymphoma Study Group (IELSG)., Haematologica. 2002 Dec;87(12):1258-64.
- 42) Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients., Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannina D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, Alinari L, Baccarani M, Tura S., Ann Oncol. 2002 Sep;13(9):1364-9.

- 43) Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy., Zinzani PL, Martelli M, Bendandi M, De Renzo A, Zaccaria A, Pavone E, Bocchia M, Falini B, Gobbi M, Gherlinzoni F, Stefoni V, Tani M, Tura S., Haematologica. 2001 Feb;86(2):187-91.
- 44) How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term, Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S., Haematologica. 1999 Nov;84(11):996-1001.
- 45) Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients., Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, Gentilini P, Guardigni L, Gobbi M, Fattori PP, Falini B, Lauta VM, Bendandi M, Gherlinzoni F, De Renzo A, Zaja F, Mazza P, Volpe E, Bocchia M, Aitini E, Tabanelli M, Leone G, Tura S., Blood. 1999 Jul 1;94(1):33-8.
- 46) Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy., Zinzani PL, Martelli M, Magagnoli M, Zaccaria A, Ronconi F, Cantonetti M, Bocchia M, Marra R, Gobbi M, Falini B, Gherlinzoni F, Moretti L, De Renzo A, Mazza P, Pavone E, Sabattini E, Amendola A, Bendandi M, Pileri SA, Mandelli F, Tura S., Blood. 1998 Aug 1;92(3):790-4.
- 47) Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma., Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S., Blood. 1997 Jun 1;89(11):3974-9.
- 48) Blood. 2000 Feb 1;95(3):783-9.
- 49) Favrot M, Philip I, Combaret V, Pavone E, Bouffet E, Biron P, Philip T. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:202-4.

I consent the treatment of the personal data contained into my Curriculum vitae according to the Decree 196/2003.

"I confirm that I have followed clinical trials according to GCP"

Firma

Tricase, 23/05/2018

